IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia.

ABSTRACT:

Background

Heparin-induced thrombocytopenia (HIT) complicated by severe thrombocytopenia and thrombosis can pose significant treatment challenges. Use of alternative anticoagulants in this setting may increase bleeding risks, especially in patients who have a protracted disease course. Additional therapies are lacking in this severely affected patient population.

Methods

We describe three patients with HIT who had severe thromboembolism and prolonged thrombocytopenia refractory to standard treatment but who achieved an immediate and sustained response to IVIg therapy. The mechanism of action of IVIg was evaluated in these patients and in five additional patients with severe HIT. The impact of a common polymorphism (H/R 131) in the platelet IgG receptor FcγRIIa on IVIg-mediat

SUBMITTER: Padmanabhan A 

PROVIDER: S-EPMC5812774 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature